Law360, New York (September 05, 2007) -- A federal appeals court panel has upheld both the validity of Forest Laboratories Inc.’s patent on the blockbuster antidepressant drug Lexapro and an injunction thwarting Ivax Pharmaceuticals Corp.’s plans to market a generic.
The U.S. Court of Appeals for the Federal Circuit ruled Wednesday that the lower court correctly rejected Ivax's argument that the patent was anticipated, obvious and impermissibly broadened upon re-issue....
